The Top 5 Analyst Questions From Exact Sciences's Q2 Earnings Call

Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the market responded negatively to the results. Management attributed the quarter’s performance to continued momentum in its Cologuard franchise, noting all-time highs in provider ordering and patient engagement. CEO Kevin Conroy highlighted that, “A record 200,000 providers ordered Cologuard with growth across all segments at record depth,” and pointed to progress in payer coverage for new products. However, management also acknowledged that temporary headwinds, including higher accounts receivable linked to the Cologuard Plus launch and one-time costs tied to a new productivity plan, impacted reported margins and cash flows.

Is now the time to buy EXAS? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Exact Sciences’s Q2 Earnings Call

• Andrew Brackmann (William Blair) asked about the strategic fit of the Freenome partnership. CEO Kevin Conroy explained it adds a blood-based option and accelerates time to market, offering flexibility for future product versions.

• Douglas Schenkel (Wolfe Research) questioned the return on investment from M&A and R&D, referencing prior acquisitions. Conroy defended past deals, emphasizing the commercial impact of Cologuard and Oncotype, and argued that blood-based screening remains a niche but additive opportunity.

• Catherine Schulte (Baird) pressed for details on the weaker-than-expected internal blood test data and FDA timelines. Conroy acknowledged disappointment, clarified that Freenome’s test fills a niche for screening refusers, and said FDA review timelines remain uncertain.

• Jack Meehan (Nephron Research) inquired about the impact of new blood-based competitors on Cologuard. Conroy observed that market entrants have actually boosted Cologuard orders by raising awareness, and that provider loyalty remains high.

• Vijay Kumar (Evercore ISI) focused on gross margin trends and guidance moderation. CFO Aaron Bloomer attributed margin fluctuations to timing of large care gap orders and reiterated that full-year margin expansion is expected despite quarter-to-quarter variability.

Catalysts in Upcoming Quarters

In future quarters, our analyst team will be tracking (1) the pace of Cologuard Plus adoption as additional payer contracts go live, (2) progress in integrating and launching the Freenome blood-based test and measuring early adoption, and (3) initial results from Cancerguard’s launch and market feedback. We will also monitor execution of the productivity plan and its impact on margin improvement.

Exact Sciences currently trades at $41.78, down from $47.17 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.